Results 121 to 130 of about 5,080 (193)

National Monthly Outpatient Claim-Recorded Lecanemab Drug Amount in Japan During Fiscal Year 2024. [PDF]

Geriatr Gerontol Int
Omura T, Kamihara T.
europepmc   +1 more source

Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study. [PDF]

Alzheimers Dement
Wu H, Chen Q, Fang M, Tang H, Liu H, Liu J, Zhang J, Chi L, Liu S, Xin J, Leng L, Wang P, Chi S, Li Y, Chen J, Zhang L, Zhang J, Ma Q, Wang X, Meng X, Nao J, Li X, Lv Y, Jia Y, Zhao Q, Liu C, Gan J, Zhu J, Song Y, Li H, Fei M, Guo X, Liu J, Peng G, Chen X, Ji Y.   +35 more
europepmc   +1 more source

Clinical Practice Outcomes With Lecanemab for Alzheimer Disease. [PDF]

Neurol Open Access
Liu AJ, Moghadam AA, Alam MS, Lutz MW, Navarra A, Luo S, Wang LA, Petrella JR, Whitson H, O'Brien RJ, Johnson KG, Parker D, Beam C, Sanfilippo M, Al-Sahlani H, Cobb S, Liu MY, Doraiswamy PM.   +17 more
europepmc   +1 more source

Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system. [PDF]

Front Pharmacol
Feng X, Bi S, Shi C, Chang Q, Zhang J, Zhuang Y.   +5 more
europepmc   +1 more source

Characterization of the Anti-Alzheimer Drug Lecanemab by Mass Spectrometry. [PDF]

ACS Omega
Sha J, Geng Z, Qi S, Du L, Hu Q, Cai M, Chen D, Chen Y, Liu S, Song H, Ling T, Chang C, Bai B.   +12 more
europepmc   +1 more source

Real-world implementation of lecanemab in Korean patients at a tertiary memory clinic: Safety, ARIA risk, and early treatment patterns. [PDF]

Alzheimers Dement (Amst)
Shin J, Suh SI, Park YJ, Lee S, Kang J, Lee ES, Jung HN, Ryoo I, Lee S, Eo JS, Oh K, Koh SB, Kang SH.   +12 more
europepmc   +1 more source

Six-month real-world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia. [PDF]

Alzheimers Dement (N Y)
Kim GH, Yoon HJ, Kim EH, Kim JY, Yeom J, Kang SY, Lee B, Jeong JH.   +7 more
europepmc   +1 more source

A comparison of the effectiveness and safety between the antibodies Donanemab and Lecanemab in early Alzheimer's disease

Introduktion: Alzheimers sjukdom (AD) är den vanligaste formen av demens. Antalet individer med demensdiagnos förväntas öka från cirka 57 miljoner år 2019 till 152,8 miljoner år 2050.
Rehnman, Sanna
core  

Lecanemab in symptomatic PSEN1 p.Met233Val early-onset Alzheimer's disease: Neuroimaging safety, regional amyloid-PET dynamics, and longitudinal plasma biomarkers. [PDF]

Alzheimers Dement (Amst)
Noh MY, Sung W, Kim H, Son B, Kim YE, Choi YY, Holtzman DM, Kim SH.   +7 more
europepmc   +1 more source

Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer's disease. [PDF]

Alzheimers Dement
Cai Y, Wang Y, Huang W, Su Y, Lei M, Jia R, Wu C, Zhang T, Sun L, Peng B, Cheng J, Yu J, Chen X, Ye Q, Yu J, Xin J.   +15 more
europepmc   +1 more source